NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD
Shares of Neuralstem (NASDAQ: CUR) plummeted 57% following the company’s release of top-line data from its exploratory phase 2 clinical trial on the efficacy of NSI-189 for Major Depressive Disorder (MDD). The trial did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS). The trial evaluated NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo. The 40 mg once daily dose was directionally positive on the MADRS. One of the trial's two secondary endpoints, the patient-rated Symptoms of Depression Questionnaire (SDQ), achieved statistical…







